News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
274,258 Results
Type
Article (14308)
Company Profile (105)
Press Release (259837)
Multimedia
Podcasts (65)
Webinars (13)
Section
Business (88432)
Career Advice (465)
Deals (15420)
Drug Delivery (73)
Drug Development (36834)
Employer Resources (50)
FDA (6392)
Job Trends (6252)
News (151004)
Policy (14151)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (445)
Accelerated approval (13)
Adcomms (8)
Allergies (67)
Alliances (23352)
ALS (56)
Alzheimer's disease (478)
Antibody-drug conjugate (ADC) (100)
Approvals (6583)
Artificial intelligence (201)
Autoimmune disease (41)
Automation (12)
Bankruptcy (150)
Best Places to Work (4388)
BIOSECURE Act (9)
Biosimilars (118)
Biotechnology (40)
Bladder cancer (38)
Brain cancer (30)
Breast cancer (171)
Cancer (1327)
Cardiovascular disease (151)
Career advice (418)
Career pathing (13)
CAR-T (52)
CDC (6)
Cell therapy (153)
Cervical cancer (9)
Clinical research (32125)
Collaboration (728)
Compensation (325)
Complete response letters (33)
COVID-19 (778)
CRISPR (43)
C-suite (432)
Cystic fibrosis (58)
Data (1826)
Denatured (18)
Depression (45)
Diabetes (126)
Diagnostics (1385)
Digital health (8)
Diversity (2)
Diversity, equity & inclusion (14)
Drug discovery (113)
Drug pricing (114)
Drug shortages (12)
Duchenne muscular dystrophy (80)
Earnings (33562)
Editorial (20)
Employer branding (4)
Employer resources (45)
Events (39057)
Executive appointments (528)
FDA (7490)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (428)
Gene editing (71)
Generative AI (18)
Gene therapy (165)
GLP-1 (445)
Government (1404)
Grass and pollen (4)
Guidances (164)
Healthcare (3578)
HIV (11)
Huntington's disease (9)
IgA nephropathy (37)
Immunology and inflammation (68)
Immuno-oncology (14)
Indications (53)
Infectious disease (842)
Inflammatory bowel disease (73)
Inflation Reduction Act (7)
Influenza (24)
Intellectual property (113)
Interviews (60)
IPO (5936)
IRA (33)
Job creations (2057)
Job search strategy (374)
JPM (28)
Kidney cancer (11)
Labor market (28)
Layoffs (205)
Leadership (8)
Legal (3457)
Liver cancer (22)
Longevity (8)
Lung cancer (184)
Lymphoma (131)
Machine learning (13)
Management (17)
Manufacturing (412)
MASH (67)
Medical device (1304)
Medtech (1311)
Mergers & acquisitions (9905)
Metabolic disorders (434)
Multiple sclerosis (46)
NASH (14)
Neurodegenerative disease (82)
Neuropsychiatric disorders (37)
Neuroscience (888)
Neurotech (1)
NextGen: Class of 2026 (1590)
Non-profit (600)
Now hiring (17)
Obesity (227)
Opinion (141)
Ovarian cancer (39)
Pain (109)
Pancreatic cancer (51)
Parkinson's disease (80)
Partnered (11)
Patents (221)
Patient recruitment (116)
Peanut (12)
People (29767)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase 1 (8345)
Phase 2 (13559)
Phase 3 (12240)
Pipeline (1915)
Policy (135)
Postmarket research (1404)
Preclinical (3350)
Press Release (25)
Prostate cancer (84)
Psychedelics (16)
Radiopharmaceuticals (135)
Rare diseases (350)
Real estate (2663)
Recruiting (18)
Regulatory (10968)
Reports (15)
Research institute (574)
Resumes & cover letters (55)
Rett syndrome (5)
RNA editing (6)
RSV (20)
Schizophrenia (69)
Series A (80)
Series B (48)
Service/supplier (2)
Sickle cell disease (46)
Special edition (10)
Spinal muscular atrophy (83)
Sponsored (9)
Startups (1648)
State (2)
Stomach cancer (5)
Supply chain (50)
Tariffs (68)
The Weekly (45)
Vaccines (231)
Venture capital (32)
Weight loss (140)
Women's health (27)
Worklife (4)
Date
Last 7 days (177)
Last 30 days (708)
Last 365 days (10424)
2026 (955)
2025 (10728)
2024 (12514)
2023 (14271)
2022 (19574)
2021 (20123)
2020 (19094)
2019 (14919)
2018 (11751)
2017 (13934)
2016 (13144)
2015 (15495)
2014 (12443)
2013 (10600)
2012 (11409)
2011 (11949)
2010 (10915)
Location
Africa (318)
Alabama (19)
Alaska (1)
Arizona (77)
Arkansas (3)
Asia (20890)
Australia (2688)
California (3195)
Canada (1482)
China (550)
Colorado (143)
Connecticut (129)
Delaware (123)
Europe (41048)
Florida (601)
Georgia (63)
Hawaii (1)
Idaho (10)
Illinois (349)
India (44)
Indiana (240)
Iowa (2)
Japan (246)
Kansas (77)
Kentucky (20)
Louisiana (4)
Maine (2)
Maryland (421)
Massachusetts (2586)
Michigan (46)
Minnesota (165)
Mississippi (1)
Missouri (33)
Montana (8)
Nebraska (7)
Nevada (16)
New Hampshire (8)
New Jersey (1396)
New Mexico (7)
New York (910)
North Carolina (620)
North Dakota (2)
Northern California (1465)
Ohio (80)
Oklahoma (5)
Oregon (18)
Pennsylvania (715)
Puerto Rico (12)
Rhode Island (17)
South America (508)
South Carolina (10)
Southern California (1387)
Tennessee (53)
Texas (454)
United States (12692)
Utah (59)
Virginia (160)
Washington D.C. (42)
Washington State (223)
West Virginia (1)
Wisconsin (37)
Wyoming (1)
274,258 Results for "servier pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Servier’s Voranigo® (vorasidenib) Receives Prix Galien Awards Across Multiple Regions
December 8, 2025
·
2 min read
Press Releases
Insilico Medicine Announce US$888 Million Multi-Year Collaboration with Servier for Drug Discovery and Development in Oncology
January 5, 2026
·
3 min read
Press Releases
Servier’s New and Updated Data at 2025 ASH Annual Meeting Highlight Commitment to Hematology Research
November 7, 2025
·
10 min read
Press Releases
Servier’s Clinical and Real-World Data at 2025 SNO Congress Showcase Leadership in IDH-Mutant Glioma
November 11, 2025
·
9 min read
Neuroscience
Servier Bets $450M On Kaerus’ Fragile X Syndrome Therapy
KER-0193 is a modulator of ion channels connected to autism spectrum disorder. The FDA bestowed orphan drug and rare pediatric drug designations on the candidate earlier this year.
September 8, 2025
·
2 min read
·
Tristan Manalac
Cancer
Servier Commits up to $530M Into Eye Cancer Deal With IDEAYA
The French giant is gaining access to darovasertib, a small molecule protein kinase C inhibitor already in Phase II/III trials, with rights for the whole world besides the U.S.
September 2, 2025
·
2 min read
·
Dan Samorodnitsky
Press Releases
Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide
September 2, 2025
·
8 min read
Press Releases
Servier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder
September 8, 2025
·
6 min read
Press Releases
Servier Announces Positive Findings from Longer-Term Analysis of the Phase 3 INDIGO Trial Showing Continued Durable Treatment Effect of VORANIGO® (vorasidenib) Published in The Lancet Oncology
November 4, 2025
·
12 min read
Approvals
Servier Gets FDA Approval for First Targeted Therapy for Grade 2 IDH-Mutant Glioma
Servier Pharmaceuticals’ vorasidenib on Tuesday secured the FDA’s green light for the treatment of patients with grade 2 gliomas carrying mutations in the IDH gene.
August 7, 2024
·
2 min read
·
Tristan Manalac
1 of 27,426
Next
